Nkarta to Participate in an Upcoming Investor Conference
Nkarta (Nasdaq: NKTX), a company focused on engineered natural killer (NK) cell therapies, has announced its upcoming participation in the Stifel 2024 Healthcare Conference. The company will participate in a fireside chat scheduled for November 19, 2024, at 10:55 a.m. ET. The event will be webcast live on Nkarta's website investor section, with a replay available for approximately 90 days afterward.
Nkarta (Nasdaq: NKTX), un'azienda focalizzata sulle terapie cellulari con cellule natural killer (NK) ingegnerizzate, ha annunciato la sua prossima partecipazione alla Stifel 2024 Healthcare Conference. L'azienda parteciperà a una chiacchierata informale programmata per il 19 novembre 2024, alle 10:55 a.m. ET. L'evento sarà trasmesso in diretta sul sito web dedicato agli investitori di Nkarta, con una registrazione disponibile per circa 90 giorni dopo.
Nkarta (Nasdaq: NKTX), una empresa centrada en terapias con células asesinas naturales (NK) diseñadas, ha anunciado su próxima participación en la Stifel 2024 Healthcare Conference. La empresa participará en una charla informal programada para el 19 de noviembre de 2024, a las 10:55 a.m. ET. El evento se transmitirá en vivo en la sección de inversores del sitio web de Nkarta, con una repetición disponible durante aproximadamente 90 días después.
Nkarta (Nasdaq: NKTX), 자연 살해 세포 (NK) 치료에 주력하는 회사가 Stifel 2024 Healthcare Conference에 참가할 예정이라고 발표했습니다. 이 회사는 2024년 11월 19일에 오전 10시 55분 ET에 예정된 간담회에 참여합니다. 이 행사는 Nkarta의 투자자 웹사이트에서 실시간으로 방송되며, 이후 약 90일 동안 다시 볼 수 있습니다.
Nkarta (Nasdaq: NKTX), une entreprise spécialisée dans les thérapies à base de cellules tueuses naturelles (NK) conçues, a annoncé sa prochaine participation à la Stifel 2024 Healthcare Conference. L'entreprise participera à une discussion informelle prévue pour le 19 novembre 2024, à 10h55 ET. L'événement sera diffusé en direct sur la section investisseur du site web de Nkarta, avec une rediffusion disponible pendant environ 90 jours après.
Nkarta (Nasdaq: NKTX), ein Unternehmen, das sich auf entwickelte natürliche Killerzellen (NK) Therapien konzentriert, hat seine bevorstehende Teilnahme an der Stifel 2024 Healthcare Conference bekannt gegeben. Das Unternehmen wird an einem Fireside-Chat teilnehmen, der für den 19. November 2024 um 10:55 Uhr ET geplant ist. Die Veranstaltung wird live auf der Investorenseite von Nkarta übertragen, mit einer Wiederholung, die etwa 90 Tage danach verfügbar sein wird.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
Stifel 2024 Healthcare Conference
November 19, 2024
10:55 a.m. ET – fireside chat
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
When is Nkarta (NKTX) presenting at the Stifel 2024 Healthcare Conference?
How can I watch Nkarta's (NKTX) presentation at the Stifel Healthcare Conference?
What type of therapies does Nkarta (NKTX) develop?
